Centessa Pharmaceuticals to be Acquired by Eli Lilly for $38.00 Cash Plus CVRs

summarizeSummary

Centessa Pharmaceuticals plc announced its definitive agreement to be acquired by Eli Lilly and Company for $38.00 per share in cash plus a Contingent Value Right (CVR) for up to an additional $9.00 per share, marking a transformational event for the company and its shareholders.

check_boxKey Events

• Definitive Acquisition Agreement

  Centessa Pharmaceuticals plc has entered into a definitive agreement to be acquired by Eli Lilly and Company, with the transaction expected to close in Q3 2026, subject to customary approvals.

• Transaction Terms

  Shareholders will receive $38.00 in cash per share, plus one non-transferable Contingent Value Right (CVR) entitling them to up to three contingent cash payments totaling $9.00 per share, based on specified regulatory milestones for cleminorexton or ORX142.

• Strategic Rationale

  The acquisition aims to advance Eli Lilly's portfolio with Centessa's orexin-based neuroscience therapeutics, particularly cleminorexton for central disorders of hypersomnolence.

• Financial Performance (FY2025)

  The company reported a net loss of $197.5 million for the year ended December 31, 2025, an improvement from $235.8 million in 2024, and held $577.1 million in cash, cash equivalents, and investments, projected to fund operations into mid-2028 prior to the acquisition.

auto_awesomeAnalysis

This 10-K filing confirms and details the definitive agreement for Eli Lilly and Company to acquire Centessa Pharmaceuticals plc, a transformational event for the clinical-stage biotechnology company. The transaction offers an upfront cash payment of $38.00 per share, with additional upside potential of up to $9.00 per share through non-transferable Contingent Value Rights (CVRs) tied to the regulatory success of key pipeline assets, cleminorexton and ORX142. This structure provides a clear exit for shareholders and allows them to benefit from the future development of these programs while de-risking their investment. The acquisition by a major pharmaceutical company like Eli Lilly validates Centessa's orexin-based neuroscience platform and its lead candidates. While the immediate cash consideration is slightly below the current market price, the total potential value with CVRs represents a significant premium. Investors should monitor the progress of regulatory approvals for the acquisition and the achievement of the CVR milestones.